The absence of significant changes in the CD4+ and CD3+ T cells could be because these populations are coupled with the activation specific regulatory cells (FOXP3+ PD-1+), suggesting a complex interplay where the combination treatment may promote regulatory pathways that could be combined for anti-tumor response. Here, FOXP3 is linked to neoplasm.